Holen Sie sich die Stockscreener-App
8.67
5.45%
-0.50
Handel nachbörslich:
8.67
Schlusskurs vom Vortag:
$9.17
Offen:
$9.055
24-Stunden-Volumen:
32,467
Relative Volume:
0.34
Marktkapitalisierung:
$162.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.71M
KGV:
-1.172
EPS:
-7.3973
Netto-Cashflow:
$-37.41M
1W Leistung:
-11.71%
1M Leistung:
+0.23%
6M Leistung:
+122.88%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.55
$9.07
1-Wochen-Bereich:
$8.55
$10.19
52-Wochen-Spanne:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Firmenname
Kalaris Therapeutics Inc
Sektor
Branche
Telefon
650-249-2727
Adresse
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
8.67 | 171.50M | 0 | -51.71M | -37.41M | -7.3973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-11-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-23 | Fortgesetzt | Piper Sandler | Neutral |
| 2025-05-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kalaris Therapeutics Inc Aktie (KLRS) Neueste Nachrichten
Raymond James Maintains Strong Buy on KLRS Kalaris Therapeutics Inc Mar 2026 - Meyka
William Blair reiterates Kalaris stock rating on TH103 potential By Investing.com - Investing.com Canada
Kalaris Therapeutics TH103: Next-Generation Anti-VEGF for Retinal Diseases Shows Promising Phase 1a Results and Extended Durability 23578 - Minichart
Stock Market Recap: Can Kalaris Therapeutics Inc weather a recessionPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay - Investing.com UK
Kalaris Updates TH103 Strategy and Highlights Cash Runway - TipRanks
Kalaris updates TH103 timelines, previews Phase 1b/2 data and extends cash runway into Q4 2027 - TradingView
Aug Analyst Calls: Is Kalaris Therapeutics Inc stock a good pick for beginners2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Kalaris Therapeutics Inc. stock benefit from green energy trendsQuarterly Trade Report & Fast Exit and Entry Strategy Plans - Naître et grandir
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
US Market Wrap: Is Kalaris Therapeutics Inc vulnerable to short sellersJuly 2025 Fed Impact & Short-Term Trading Alerts - baoquankhu1.vn
KLRS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kalaris Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
KLRS Should I Buy - Intellectia AI
Published on: 2026-02-28 06:52:09 - baoquankhu1.vn
ETFs Investing in Kalaris Therapeutics, Inc. Stocks - TradingView
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold - MarketBeat
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therape - GuruFocus
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therapeutics Inc - GuruFocus
Sell Signal: Is CRISPR Therapeutics AG backed by strong institutional buyingGold Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Kalaris Therapeutics Insider Bought Shares Worth $5,000,006, According to a Recent SEC Filing - marketscreener.com
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock - MarketBeat
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares By Investing.com - Investing.com South Africa
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares - Investing.com Australia
Akkaraju group reports 56.5% Kalaris (KLRS) ownership stake - Stock Titan
RTW discloses 5.7% Kalaris Therapeutics (KLRS) ownership stake - Stock Titan
Earnings Miss: How Kalaris Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Action & Weekly Market Pulse Alerts - mfd.ru
Is Kalaris Therapeutics Inc. undervalued by DCF analysisSwing Trade & Capital Efficiency Focused Ideas - mfd.ru
Will Kalaris Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Fast Gain Stock Tips - mfd.ru
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Kalaris Therapeutics Inc. stock is trending among retail tradersQuarterly Investment Review & High Return Trade Opportunity Guides - mfd.ru
Kalaris Therapeutics Emerges with Focused Retinal Disease Strategy - AD HOC NEWS
Institution Moves: Whats the profit margin of Kalaris Therapeutics IncTrade Exit Report & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8% - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Smart Money: Should I add Kalaris Therapeutics Inc stock to my portfolioJuly 2025 Big Picture & Real-Time Buy Signal Notifications - baoquankhu1.vn
Kalaris to present phase 1 data of novel eye therapy at Macula Society - Investing.com Australia
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting - Investing News Network
Kalaris Therapeutics raises $50M privately - MSN
What’s the MACD signal for Kalaris Therapeutics Inc.Double Top/Bottom Patterns & High Return Capital Strategies - bollywoodhelpline.com
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Buyback Watch: Will Kalaris Therapeutics Inc outperform small cap indexesJuly 2025 Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Swing Trade: Is Kalaris Therapeutics Inc. affected by consumer sentimentInsider Buying & AI Forecasted Stock Moves - baoquankhu1.vn
Support Test: What is Kalaris Therapeutics Incs 5 year growth outlookRecession Risk & AI Powered Market Entry Ideas - baoquankhu1.vn
Finanzdaten der Kalaris Therapeutics Inc-Aktie (KLRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):